carboplatin + docetaxel + nimotuzumab

This is a combination regimen consisting of three agents: - **Carboplatin** (a platinum-based chemotherapeutic agent that induces DNA crosslinking and apoptosis in rapidly dividing cells), - **Docetaxel** (a taxane-class chemotherapeutic that stabilizes microtubules, inhibiting cell division), and - **Nimotuzumab** (a humanized monoclonal antibody targeting the epidermal growth factor receptor [EGFR], blocking ligand binding and downstream signaling). The combination has been studied primarily in advanced non-small cell lung cancer (NSCLC), where nimotuzumab is added to standard chemotherapy with carboplatin and docetaxel. The rationale is to enhance antitumor efficacy by combining cytotoxic effects with targeted inhibition of EGFR-mediated tumor growth. Clinical studies indicate this regimen can prolong progression-free survival compared to chemotherapy alone, with an acceptable safety profile[1][2][3].